ロード中...
What Path Do We Take?
As existing biologics gain indications and new drugs make it to market, the array of choices makes it challenging to pick the right treatment for a given patient. Clinical effectiveness is the most important factor, but at the policy level, cost has to enter the discussion. Where?
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioCommunications LLC
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2706158/ https://ncbi.nlm.nih.gov/pubmed/22478710 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|